Hemal Mehta

Associate Professor @JohnsHopkinsEPI | Pharmacoepidemiology

[Hemal Mehta @mehtahemal]

Excited to share our JAMA IM review, where we found that GLP-1s show similar weight-loss effects across age, race/ethnicity, BMI, and HbA1c, with a modestly greater benefit in women.
https://t.co/x2II85nFqB

[JAMA Internal Medicine @JAMAInternalMed]

Among adults treated with glucagon-like peptide-1 receptor agonists (#GLP-1 RAs) for weight loss, efficacy was greater in women than men, but similar across age, race, ethnicity, baseline body mass index, and hemoglobin A1c.

https://t.co/SHqKASSIX4

[Hemal Mehta @mehtahemal]

@Lizstuartdc @jhubiostat @JohnsHopkinsSPH Great news. Congratulations!!

[Annals of Int Med @AnnalsofIM]

New from @JohnsHopkinsSPH @mehtahemal: #S-Elixhauser is well calibrated and internally validated but advantage over the #AHRQ Elixhauser and #Charlson summary scores for determining in-hospital, 30-day, and 1-year mortality is unclear: https://t.co/uGfvWeXlM4

[UTMB Sealy Center on Aging & NIA Pepper Center @UTMB_SCOA]

During the SARS-CoV-2 pandemic, we found prolonged increases in mortality rates after hospitalization for non-SARS-CoV-2 illnesses. Learn more about a new study in @JAMANetworkOpen at our website: https://t.co/lm9ncfHiDm

@PepperOAIC #SCOA #COVID19

[JAMA Network Open @JAMANetworkOpen]

During the #COVID19 pandemic, this cohort study found prolonged increases in mortality rates after hospitalization for non-#SARSCoV2 illnesses. @UTMB_SCOA @UTMBHealth https://t.co/aoGS04Z5Jb

[Johns Hopkins Bloomberg School of Public Health @JohnsHopkinsSPH]

"This is my body, I have to defend it!" 🏠

Reminder: Being vaccinated and boosted is your best line of defense against severe illness from COVID-19.

Subscribe to our newsletter for the latest info: https://t.co/3vRukdJJEk

[Hemal Mehta @mehtahemal]

@Rishidesai11 @MichaelEMatheny @kbjohnsonmd @lmhcurtis @darrentoh_epi Important work and nicely presented. Congratulations!

[The Lancet Rheumatology @TheLancetRheum]

NEW RESEARCH—Long-term use of immunosuppressive medicines and in-hospital #COVID19 outcomes: data from N3C shows no increased risk of mechanical ventilation or in-hospital death with the exception of #rituximab https://t.co/vEyTzfvK5q #LancetRheumatology
@JohnsHopkins

[Hopkins Med News @HopkinsMedNews]

.@Hopkins_GIM expert and @JohnsHopkinsSPH experts find #drug increases #risk for #death in older adults with #Parkinsons Disease @mehtahemal
https://t.co/GH2UlauDZT

[Hemal Mehta @mehtahemal]

@SBAmin @JohnsHopkinsEPI @ncats_nih_gov Thank you!

[Hemal Mehta @mehtahemal]

There has been an enormous effort to find new or repurposed drugs for the treatment of COVID-19. We did this study to understand the use of drugs and how use varied across patients and health systems. @JohnsHopkinsEPI @ncats_nih_gov

[Annals of Int Med @AnnalsofIM]

New from @JohnsHopkinsSPH #dexamethasone underused among mechanically ventilated patients hospitalized with #COVID19 https://t.co/q7bt181zde

[Hemal Mehta @mehtahemal]

@Rishidesai11 @JohnsHopkinsEPI @ncats_nih_gov Thank you!

[Johns Hopkins Bloomberg School of Public Health @JohnsHopkinsSPH]

“These findings underscore the wide variation in COVID-19 care across American health systems,” says study lead author and @JohnsHopkinsEPI faculty @MehtaHemal. https://t.co/6rh6a6zcf4

[Hemal Mehta @mehtahemal]

A BIG thanks to the N3C pharmacoepi team for the amazing team effort and all the people who help build the #N3C

[Hemal Mehta @mehtahemal]

Please check out this editorial that nicely puts our findings in context https://t.co/L9miNxc9Uy